2026-04-13T16:53:15Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/134372025-10-24T10:33:50Zcom_2072_451665com_2072_378040com_2072_378070col_2072_451666col_2072_378092

00925njm 22002777a 4500 dc Garcia‑Guiñon, Antoni author Andrea Charry, Paola author Jimenez, María author Sarrà-Escandell, Josep author Delgado, Izarbe author Segura de la Torre, Laura author Garcia-Pintos, Marta author Gonzalez, Yolanda author Sancho, Esther author Senín, Alicia author 2025-07-22T10:52:57Z 2025-07-22T10:52:57Z 2025-02 Carfilzomib, lenalidomide and dexamethasone; Real-world; Relapsed/refractory multiple myeloma Carfilzomib, lenalidomida y dexametasona; Mundo real; Mieloma múltiple recidivante/refractario Carfilzomib, lenalidomida i dexametasona; Món real; Mieloma múltiple recidivant/refractari Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planned to include at least 100-150 patients. In total 194 patients were included. Median age was 64 years (range: 40-88) and 56% were male. All patients had received bortezomib. Additionally, 89 patients (46%) had received thalidomide and 29 (15%) lenalidomide. The ORR was 73% (95% CI: 66-79), with 72 patients (37%) having ≥ CR. The ORR was influenced by ISS score, number of previous treatments and exposure to lenalidomide. The median PFS was 26 months and 2-years OS rate 70%. The ISS stage and LDH levels were independent prognostic factors of survival. In conclusion, the KRd scheme led to a good effectiveness comparable safety profile to the phase III clinical trial in patients with RRMM. http://hdl.handle.net/11351/13437 Mieloma múltiple Quimioteràpia combinada Anàlisi de supervivència (Biometria) DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols Other subheadings::Other subheadings::Other subheadings::/administration & dosage CHEMICALS AND DRUGS::Polycyclic Compounds::Fused-Ring Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienetriols::Dexamethasone Other subheadings::Other subheadings::Other subheadings::/adverse effects CHEMICALS AND DRUGS::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Phthalic Acids::Phthalimides::Lenalidomide Other subheadings::Other subheadings::Other subheadings::/adverse effects ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada Otros calificadores::Otros calificadores::Otros calificadores::/administración & dosificación COMPUESTOS QUÍMICOS Y DROGAS::compuestos policíclicos::compuestos con anillos de fusión::esteroides::pregnanos::pregnadienos::pregnadienotrioles::dexametasona Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::ácidos carboxílicos::ácidos carbocíclicos::ácidos ftálicos::ftalimidas::lenalidomida Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma